Recent 8-K filings for TEM
Highest-materiality recent filing
Tempus AI to acquire Personalis for $16.25/share; stock/cash mix; exchange ratio tied to TEM price
- Per share consideration: $16.25 cash or stock based on exchange ratio; Tempus may elect cash for up to 50% of shares.
- Exchange ratio fixed at 0.3356 if TEM stock price ≤ $48.42; otherwise $16.25 / TEM 15-day VWAP.
-
Tempus AI Q2 revenue $382.5M (+22% YoY); raises FY2026 guidance to $1.595-1.605B
Revenue $382.5M, up 22% YoY; GAAP net income $5.6M vs loss $42.8M in Q2 2025.
-
Tempus AI to acquire Personalis for $16.25/share; stock/cash mix; exchange ratio tied to TEM price
Per share consideration: $16.25 cash or stock based on exchange ratio; Tempus may elect cash for up to 50% of shares.
-
Tempus AI to acquire Personalis for $1.5B, adding MRD technology to precision oncology platform
Total enterprise value of $1.5B net of Tempus' existing stake; $16.25 per share in stock, with Tempus option to pay up to 50% cash.
-
Tempus AI closes $460M 0% convertible notes due 2032; repays $307.7M credit facility
Issued $460M aggregate principal of 0.00% Convertible Senior Notes due 2032, conversion price ~$69.26/share.
-
Tempus AI Q1 revenue $348M (+36% YoY); raises FY2026 guidance to $1.59-1.60B
Revenue $348.1M, +36% YoY; Diagnostics $261.1M (+34.7%), Data & Apps $87.0M (+40.5%).
-
Tempus AI Q4 revenue $367.2M (+83% YoY); guides FY26 revenue ~$1.59B, adj. EBITDA ~$65M
Q4 revenue $367.2M (+83% YoY, 33.5% organic); Diagnostics $266.9M (+121.6%) with Oncology volume +29%, Hereditary +23%.
-
Tempus AI reports preliminary FY2025 revenue ~$1.27B (+83% YoY); TCV exceeds $1.1B
FY2025 revenue ~$1.27B (+83% YoY); diagnostics ~$955M (+111%), data/apps ~$316M (+31%).
-
Tempus AI Q3 revenue $334M (+84.7% YoY); turns positive adjusted EBITDA; raises FY guidance
Revenue $334.2M, +84.7% YoY; gross profit $209.9M, +98.4% YoY.
-
Tempus AI closes $750M 0.75% convertible note offering, repays $274.7M term loans
Issued $750M aggregate principal of 0.75% Convertible Senior Notes due July 15, 2030, including full over-allotment.
-
Tempus Q1 revenue up 75.4% to $255.7M; raises FY2025 revenue guidance to $1.25B
Revenue $255.7M (+75.4% YoY); gross profit $155.2M (+99.8% YoY) with margin improvement in Genomics and Data & Services.
-
AstraZeneca pays Tempus $35M under MSA for foundational multimodal oncology model developed by Pathos using Tempus de-identified data.
-
Tempus AI Q4 revenue $200.7M (+35.8% YoY); guides FY25 revenue ~$1.24B, Adj. EBITDA ~$5M
Q4 revenue $200.7M (+35.8% YoY); Genomics $120.4M, Data $80.2M. Gross profit $122.1M (+49.7%).
-
Tempus AI borrows $300M to fund Ambry Genetics acquisition – term loans and revolver
Borrowed $200M in incremental term loans and $100M in revolving loans on Feb 3, 2025.
-
Tempus AI Q4 2024 revenue ~$200M (+35% YoY); full year ~$693M (+30%)
Preliminary Q4 2024 revenue ~$200M, up ~35% YoY; full-year revenue ~$693M, up ~30%.
-
Tempus AI to acquire Ambry Genetics for $375M cash plus ~4.84M shares
Acquisition of Ambry Genetics (genetic testing) for $375M cash + 4,843,136 TEM shares valued at ~$46.46/share avg VWAP.
-
Tempus AI Q3 revenue $180.9M (+33% YoY), net loss $75.8M, agrees to buy Ambry Genetics for $600M
Q3 revenue $180.9M (+33% YoY); net loss $75.8M (incl. $22.2M stock comp); Adj EBITDA -$21.8M (improved $14.4M YoY).
-
Tempus AI invests $17.7M in Personalis, exercises warrants for 9.2M shares
Purchased 3,500,000 Personalis shares at $5.07/share, aggregate $17,745,000.
-
Tempus Q2 revenue $166M, up 25% YoY; guides FY2024 revenue ~$700M
Revenue $166.0M (+25% YoY); data licensing grew 40% YoY; genomics revenue $112.3M (+22.2%).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.80 · Most common event earnings